EP3151850A4 - Formes cristallines - Google Patents

Formes cristallines Download PDF

Info

Publication number
EP3151850A4
EP3151850A4 EP15803592.3A EP15803592A EP3151850A4 EP 3151850 A4 EP3151850 A4 EP 3151850A4 EP 15803592 A EP15803592 A EP 15803592A EP 3151850 A4 EP3151850 A4 EP 3151850A4
Authority
EP
European Patent Office
Prior art keywords
crystal forms
crystal
forms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP15803592.3A
Other languages
German (de)
English (en)
Other versions
EP3151850A1 (fr
Inventor
Shuang Chen
Bradley D. Gates
Ahmad Y. Sheikh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Inc filed Critical AbbVie Inc
Priority to EP24151934.7A priority Critical patent/EP4403223A2/fr
Publication of EP3151850A1 publication Critical patent/EP3151850A1/fr
Publication of EP3151850A4 publication Critical patent/EP3151850A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EP15803592.3A 2014-06-06 2015-06-05 Formes cristallines Withdrawn EP3151850A4 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP24151934.7A EP4403223A2 (fr) 2014-06-06 2015-06-05 Formes cristallines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462008786P 2014-06-06 2014-06-06
PCT/US2015/034371 WO2015188045A1 (fr) 2014-06-06 2015-06-05 Formes cristallines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP24151934.7A Division EP4403223A2 (fr) 2014-06-06 2015-06-05 Formes cristallines

Publications (2)

Publication Number Publication Date
EP3151850A1 EP3151850A1 (fr) 2017-04-12
EP3151850A4 true EP3151850A4 (fr) 2017-11-29

Family

ID=54767417

Family Applications (2)

Application Number Title Priority Date Filing Date
EP24151934.7A Pending EP4403223A2 (fr) 2014-06-06 2015-06-05 Formes cristallines
EP15803592.3A Withdrawn EP3151850A4 (fr) 2014-06-06 2015-06-05 Formes cristallines

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP24151934.7A Pending EP4403223A2 (fr) 2014-06-06 2015-06-05 Formes cristallines

Country Status (8)

Country Link
US (2) US9321807B2 (fr)
EP (2) EP4403223A2 (fr)
JP (3) JP2017518319A (fr)
CN (1) CN106413736A (fr)
AU (2) AU2015269306B2 (fr)
CA (1) CA2948902C (fr)
MX (1) MX2016016127A (fr)
WO (1) WO2015188045A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2948902C (fr) * 2014-06-06 2022-11-22 Abbvie Inc. Formes cristallines d'inhibiteurs de protease du virus de l'hepatite c (vhc) et leur utilisation
WO2021137256A1 (fr) 2020-01-03 2021-07-08 Mylan Laboratories Limited Formes polymorphes de glecaprévir
GB202113944D0 (en) * 2021-09-29 2021-11-10 Univ Liverpool Injectable formulations

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011025849A1 (fr) * 2009-08-27 2011-03-03 Merck Sharp & Dohme Corp. Procédés de préparation d’inhibiteurs de protéase du virus de l’hépatite c
US20120070416A1 (en) * 2010-09-21 2012-03-22 Enanta Pharmaceuticals, Inc. Macrocyclic Proline Derived HCV Serine Protease Inhibitors
WO2014011840A1 (fr) * 2012-07-12 2014-01-16 Abbvie Inc. Formes cristallines d'un inhibiteur du vhc
WO2015061742A2 (fr) * 2013-10-25 2015-04-30 Abbvie, Inc. Méthodes de traitement du vhc

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604234A (en) 1991-09-05 1997-02-18 Abbott Laboratories Substituted thiol macrolactam immunomodulators
UY28240A1 (es) * 2003-03-27 2004-11-08 Boehringer Ingelheim Pharma Fases cristalinas de un potente inhibidor de la hcv
KR100995390B1 (ko) * 2006-01-02 2010-11-19 주식회사 삼양제넥스 무정형, 무수결정형 또는 수화 결정형 도세탁셀의 제조방법
RS52534B (en) * 2008-07-22 2013-04-30 Merck Sharp & Dohme Corp. MACROCYCLIC COMPOUNDS OF HINOXALINE AS HCV NS3 PROTEASE INHIBITORS
US9073825B2 (en) * 2011-08-19 2015-07-07 Merck Sharp & Dohme Limited Methods and intermediates for preparing macrolactams
CA2948902C (fr) * 2014-06-06 2022-11-22 Abbvie Inc. Formes cristallines d'inhibiteurs de protease du virus de l'hepatite c (vhc) et leur utilisation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011025849A1 (fr) * 2009-08-27 2011-03-03 Merck Sharp & Dohme Corp. Procédés de préparation d’inhibiteurs de protéase du virus de l’hépatite c
US20120070416A1 (en) * 2010-09-21 2012-03-22 Enanta Pharmaceuticals, Inc. Macrocyclic Proline Derived HCV Serine Protease Inhibitors
WO2014011840A1 (fr) * 2012-07-12 2014-01-16 Abbvie Inc. Formes cristallines d'un inhibiteur du vhc
WO2015061742A2 (fr) * 2013-10-25 2015-04-30 Abbvie, Inc. Méthodes de traitement du vhc

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CAIRA ED - MONTCHAMP JEAN-LUC: "Crystalline Polymorphism of Organic Compounds", TOPICS IN CURRENT CHEMISTRY; [TOPICS IN CURRENT CHEMISTRY], SPRINGER, BERLIN, DE, vol. 198, 1 January 1998 (1998-01-01), pages 163 - 208, XP008166276, ISSN: 0340-1022 *

Also Published As

Publication number Publication date
AU2015269306A1 (en) 2016-12-22
JP2017518319A (ja) 2017-07-06
US9321807B2 (en) 2016-04-26
US20160220487A1 (en) 2016-08-04
MX2016016127A (es) 2017-02-23
CA2948902A1 (fr) 2015-12-10
JP2023089125A (ja) 2023-06-27
AU2020239679A1 (en) 2020-10-15
US9561181B2 (en) 2017-02-07
WO2015188045A1 (fr) 2015-12-10
EP4403223A2 (fr) 2024-07-24
EP3151850A1 (fr) 2017-04-12
US20150353600A1 (en) 2015-12-10
AU2015269306B2 (en) 2020-06-25
JP2021113192A (ja) 2021-08-05
CN106413736A (zh) 2017-02-15
CA2948902C (fr) 2022-11-22

Similar Documents

Publication Publication Date Title
EP3171299A4 (fr) Multicarte à puce
EP3137941A4 (fr) Dispositifs électrochromiques
EP3129108A4 (fr) Planche a lévitation
EP3204975A4 (fr) Conduction de pile à combustible à oxyde solide
EP3106917A4 (fr) Dispositif lcd
EP3158387A4 (fr) Afficheur unidirectionnel
EP2897004B8 (fr) Pièce d'horlogerie
EP3184498A4 (fr) Élément d'entretoise
EP3123928A4 (fr) Lunettes
EP3128378A4 (fr) Pièce d'horlogerie
EP3177962A4 (fr) Dispositifs électrochromiques
EP3228352A4 (fr) Électro-stimulateur
EP3210147A4 (fr) Élément d'affichage sécurisé
EP3214112A4 (fr) Élément
EP3178972A4 (fr) SUBSTRAT MONOCRISTALLIN À BASE DE Ga2O3
EP3214504A4 (fr) Objet d'affichage
EP3238557A4 (fr) Salopette pour enfant
EP3166949A4 (fr) Thiénothiophène-isoindigo
EP3151850A4 (fr) Formes cristallines
EP3170928A4 (fr) Cristal de gaas
EP3202374A4 (fr) Orthèse
EP3199528A4 (fr) Abscinazole
EP3110412A4 (fr) 4-benzylsulfonyl-2-butènenitrile
AU2014905171A0 (en) GroundControl
AU2014905168A0 (en) 1a

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20161220

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20171102

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/12 20060101AFI20171025BHEP

Ipc: C07K 5/083 20060101ALI20171025BHEP

Ipc: A61P 31/14 20060101ALI20171025BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1236129

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20180726

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20190712

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

INTC Intention to grant announced (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20200527

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

INTC Intention to grant announced (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20210224

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

INTC Intention to grant announced (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20211125

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

INTC Intention to grant announced (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20220901

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

INTC Intention to grant announced (deleted)
P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230530

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20230906

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20240117